×
0 0 0 0 0 0 0 0
Stockreport

Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

RA PHARMACEUTICALS (RARX)  More Company Research Source: Business Wire
Last ra pharmaceuticals earnings: 8/8 07:15 am Check Earnings Report
US:NASDAQ Investor Relations: rapharma.com/news-investors
PDF 21 PNH patients completed 12-week dosing period and 16 continue on long-term extension study Dosing ongoing in Phase 2 study in generalized myasthenia gravis and Phase 1b study to support expansion into atypical hemolytic uremic syndrome and lupus nephritis CAMBRIDGE, Mass--(BUSINESS WIRE)-- Ra Pharmaceuticals, Inc. (NASDAQ:RARX) announced today the completion of dosing and topline data for the Company’s global Phase 2 clinical program evaluating RA101495 SC for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as a novel, subcutaneously-administered (SC) inhibitor of complement component 5 (C5) for treatment of PNH, generalized myasthenia gravis (gMG) and severe, debilitating renal diseases, [Read more]

IMPACT SNAPSHOT EVENT TIME: RARX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS